TWI370137B - Human monoclonal antibodies to activin receptor-like kinase-1 - Google Patents

Human monoclonal antibodies to activin receptor-like kinase-1

Info

Publication number
TWI370137B
TWI370137B TW095132933A TW95132933A TWI370137B TW I370137 B TWI370137 B TW I370137B TW 095132933 A TW095132933 A TW 095132933A TW 95132933 A TW95132933 A TW 95132933A TW I370137 B TWI370137 B TW I370137B
Authority
TW
Taiwan
Prior art keywords
kinase
monoclonal antibodies
human monoclonal
activin receptor
activin
Prior art date
Application number
TW095132933A
Other languages
English (en)
Chinese (zh)
Other versions
TW200801043A (en
Inventor
Michael Aidan North
Karin Kristina Amundson
Vahe Bedian
Shelley Sims Belouski
Dana Dan Hu-Lowe
Xin Jiang
Shannon Marie Karlicek
Sirid-Aimee Kellermann
James Arthur Thomson
Jianying Wang
Grant Raymond Wickman
Jingchuan Zhang
Original Assignee
Amgen Fremont Inc
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37906640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI370137(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Fremont Inc, Pfizer filed Critical Amgen Fremont Inc
Publication of TW200801043A publication Critical patent/TW200801043A/zh
Application granted granted Critical
Publication of TWI370137B publication Critical patent/TWI370137B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
TW095132933A 2005-09-07 2006-09-06 Human monoclonal antibodies to activin receptor-like kinase-1 TWI370137B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71529205P 2005-09-07 2005-09-07

Publications (2)

Publication Number Publication Date
TW200801043A TW200801043A (en) 2008-01-01
TWI370137B true TWI370137B (en) 2012-08-11

Family

ID=37906640

Family Applications (5)

Application Number Title Priority Date Filing Date
TW095132933A TWI370137B (en) 2005-09-07 2006-09-06 Human monoclonal antibodies to activin receptor-like kinase-1
TW101141374A TWI453218B (zh) 2005-09-07 2006-09-06 針對類活化素受體激酶－１之人類單株抗體
TW103116433A TWI541253B (zh) 2005-09-07 2006-09-06 針對類活化素受體激酶-１之人類單株抗體
TW099108743A TWI389919B (zh) 2005-09-07 2006-09-06 針對類活化素受體激酶－１之人類單株抗體
TW103138817A TWI569807B (zh) 2005-09-07 2006-09-06 針對類活化素受體激酶-１之人類單株抗體

Family Applications After (4)

Application Number Title Priority Date Filing Date
TW101141374A TWI453218B (zh) 2005-09-07 2006-09-06 針對類活化素受體激酶－１之人類單株抗體
TW103116433A TWI541253B (zh) 2005-09-07 2006-09-06 針對類活化素受體激酶-１之人類單株抗體
TW099108743A TWI389919B (zh) 2005-09-07 2006-09-06 針對類活化素受體激酶－１之人類單株抗體
TW103138817A TWI569807B (zh) 2005-09-07 2006-09-06 針對類活化素受體激酶-１之人類單株抗體

Country Status (40)

Country Link
US (3) US7537762B2 (enExample)
EP (4) EP2447283B1 (enExample)
JP (3) JP5161777B2 (enExample)
KR (3) KR101536487B1 (enExample)
CN (2) CN101517068B (enExample)
AP (2) AP2723A (enExample)
AR (2) AR055152A1 (enExample)
AU (1) AU2006297571B2 (enExample)
BR (1) BRPI0615766A2 (enExample)
CA (1) CA2621371C (enExample)
CL (1) CL2010000096A1 (enExample)
CR (3) CR9819A (enExample)
CY (1) CY1120794T1 (enExample)
DK (3) DK2960253T3 (enExample)
DO (1) DOP2006000195A (enExample)
EA (2) EA201300320A1 (enExample)
ES (3) ES2421146T3 (enExample)
GE (1) GEP20125398B (enExample)
GT (1) GT200600406A (enExample)
HN (1) HN2006031275A (enExample)
HU (2) HUE025608T2 (enExample)
IL (2) IL189642A (enExample)
LT (1) LT2960253T (enExample)
MA (1) MA29843B1 (enExample)
ME (1) ME00501B (enExample)
MY (1) MY164457A (enExample)
NL (1) NL1032452C2 (enExample)
NO (1) NO20081718L (enExample)
NZ (1) NZ566774A (enExample)
PE (1) PE20080035A1 (enExample)
PL (3) PL1933871T3 (enExample)
PT (3) PT2960253T (enExample)
RS (1) RS54393B1 (enExample)
SI (3) SI2447283T1 (enExample)
TN (1) TNSN08080A1 (enExample)
TW (5) TWI370137B (enExample)
UA (1) UA94060C2 (enExample)
UY (1) UY29783A1 (enExample)
WO (1) WO2007040912A2 (enExample)
ZA (1) ZA200802971B (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
US7897581B2 (en) * 2005-02-24 2011-03-01 Massachusetts Eye & Ear Infirmary Methods and compounds for promoting vessel regression
UA94060C2 (ru) * 2005-09-07 2011-04-11 Эмджен Фримонт Инк. Моноклональное антитело, которое специфически связывает alk-1
EP1986632B1 (en) * 2006-02-10 2012-08-15 Nerviano Medical Sciences S.R.L. Combinations comprising a cdk inhibitor and a growth factor antibody or anti-mitotic
AU2012265564B2 (en) * 2006-09-08 2016-05-26 Amgen Inc Anti-activin A antibodies and uses thereof
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
EP3181580A1 (en) * 2006-11-02 2017-06-21 Acceleron Pharma Inc. Alk1 receptor and ligand antagonists and uses thereof
AU2016247166B2 (en) * 2006-11-02 2018-09-27 Acceleron Pharma Inc. ALK1 receptor and ligand antagonists and uses thereof
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
TWI573802B (zh) 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
GT200800034A (es) * 2007-04-02 2010-03-16 Anticuerpos anti-ige
ITTV20070126A1 (it) 2007-07-16 2009-01-17 Luca Toncelli Procedimento ed apparecchiatura per la fabbricazione di lastre ad effet-to venato
AR070032A1 (es) * 2007-11-09 2010-03-10 Genentech Inc Composiciones y metodos de uso de antagonistas quinasa-1 similar al receptor de la activina (alk-1)
SG186000A1 (en) * 2007-11-12 2012-12-28 U3 Pharma Gmbh Axl antibodies
CA2712000A1 (en) * 2008-01-28 2009-08-06 Medimmune Limited Stabilized angiopoietin-2 antibodies and uses thereof
US7855564B2 (en) * 2008-02-14 2010-12-21 Delaware Capital Formation, Inc. Acoustic wave device physical parameter sensor
WO2009130296A2 (en) * 2008-04-25 2009-10-29 Morphosys Ag Anti-alk1 antibodies and uses thereof
KR20200079567A (ko) * 2008-05-02 2020-07-03 악셀레론 파마 인코포레이티드 혈관신생 및 혈관주위세포 적용범위의 조정을 위한 ａｌｋ１ 길항제 기재의 방법 및 조성물
CA2724525A1 (en) * 2008-05-15 2009-11-19 Acceleron Pharma, Inc. Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
HUE032090T2 (en) 2008-11-26 2017-09-28 Amgen Inc Stabilized variants of activin IIB receptor
WO2010126169A1 (ja) * 2009-04-30 2010-11-04 協和発酵キリン株式会社 Alk1阻害剤を有効成分とする血管障害を抑制するための医薬組成物
GB0915515D0 (en) * 2009-09-04 2009-10-07 Ucl Business Plc Treatment of vasculoproliferative conditions
KR20120110175A (ko) * 2009-12-29 2012-10-09 에프. 호프만-라 로슈 아게 항체 제제
JP2013532971A (ja) 2010-06-25 2013-08-22 バッシボディ アクスイェ セルスカプ ホモ二量体タンパク質コンストラクト
BR112014015003A2 (pt) 2011-12-19 2019-09-24 Amgen Inc composição farmacêutica, método para tratar um cancer e método para reduzir o tamanho de uma massa tumoral
TW201341401A (zh) 2012-01-09 2013-10-16 Covx Technologies Ireland Ltd 突變抗體及其共軛
EP2836514A4 (en) 2012-04-13 2015-12-30 Childrens Medical Center TIKI INHIBITORS
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
EA201591423A1 (ru) 2013-02-01 2016-01-29 Санта Мария Биотерапевтикс, Инк. Введение антитела к активину-а пациентам
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
EP2787006B1 (en) 2013-04-02 2018-02-28 Miltenyi Biotec GmbH Anti-CD8 antibody which binding is Ca2+ dependent
EP3041863A4 (en) 2013-09-05 2017-08-16 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
MX377275B (es) 2014-05-16 2025-03-07 Amgen Inc Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2).
WO2016054053A2 (en) * 2014-09-29 2016-04-07 Duke University Hiv-1 antibodies and uses thereof (adcc and bispecific abs)
GB201503438D0 (en) 2015-02-27 2015-04-15 Ucl Business Plc Antibodies
WO2016193872A2 (en) 2015-06-05 2016-12-08 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
KR101983013B1 (ko) * 2015-09-25 2019-05-28 동우 화인켐 주식회사 필름 터치 센서 및 그 제조 방법
JP2017077830A (ja) * 2015-10-21 2017-04-27 Ｋｙｂ株式会社 電動パワーステアリング装置
CA3008437A1 (en) 2016-01-08 2017-07-13 Vaccibody As Therapeutic anticancer neoepitope vaccine
EP3413912A4 (en) 2016-02-11 2019-09-25 The Johns Hopkins University COMPOSITIONS AND METHODS FOR TARGETING ACTIVIN SIGNALING FOR THE TREATMENT OF CANCER
RU2615908C1 (ru) * 2016-05-16 2017-04-11 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ моделирования лимфогенного и гематогенного метастазирования мышиной меланомы В16 у белых нелинейных крыс
AU2017306709A1 (en) 2016-08-05 2019-03-14 Humabs, BioMed SA Anti-o2 antibodies and uses thereof
SG11201903063UA (en) 2016-10-19 2019-05-30 Medimmune Llc Anti-o1 antibodies and uses thereof
EP3596225A1 (en) 2017-03-14 2020-01-22 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
CN111954719B (zh) 2018-03-26 2025-07-18 美国安进公司 细胞培养物中产生的抗体的总去岩藻糖基化糖型
BR112022005583A2 (pt) 2019-09-26 2022-09-20 Amgen Inc Métodos para a produção de composições de anticorpos
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
CN115340600B (zh) * 2020-08-19 2025-01-24 重庆医科大学 新冠病毒rbd特异性单克隆抗体和应用
AU2021360897A1 (en) 2020-10-15 2023-05-25 Amgen Inc. Relative unpaired glycans in antibody production methods
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
WO2023278341A1 (en) * 2021-06-28 2023-01-05 Trellis Bioscience, Inc. Anti-alk antibodies & uses thereof
CN115746142A (zh) * 2021-09-03 2023-03-07 开拓药业(广东)有限公司 抗alk-1/抗vegf双特异性抗体及其应用
WO2023059607A1 (en) 2021-10-05 2023-04-13 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
CN121079328A (zh) * 2023-01-18 2025-12-05 开拓药业(广东)有限公司 抗alk-1抗体及其用途
WO2024211796A1 (en) 2023-04-07 2024-10-10 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)
WO2024220916A1 (en) 2023-04-20 2024-10-24 Amgen Inc. Methods of determining relative unpaired glycan content
WO2025038600A1 (en) 2023-08-14 2025-02-20 Amgen Inc. Methods for reducing yellow color
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
JP2532858B2 (ja) 1985-04-01 1996-09-11 セルテツク リミテツド 形質転換したミエロ―マ細胞系
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
JPH0341802A (ja) 1989-07-07 1991-02-22 Ngk Spark Plug Co Ltd 温度補償型マイクロ波ストリップラインフィルタ
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0546091B1 (en) 1990-08-29 2007-01-24 Pharming Intellectual Property BV Homologous recombination in mammalian cells
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
DK1279731T3 (da) 1991-03-01 2007-09-24 Dyax Corp Fremgangsmåde til udvikling af bindende miniproteiner
DK1471142T3 (da) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
US5679666A (en) 1991-11-22 1997-10-21 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
US5770592A (en) 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
NZ257631A (en) 1992-11-17 1996-03-26 Ludwig Inst Cancer Res Serine/threonine kinase domain-containing protein, dna and hosts therefor
US7592428B1 (en) 1992-11-17 2009-09-22 Ludwig Institute For Cancer Research Antibodies which bind specifically to activin receptor like kinases
US6692925B1 (en) 1992-11-17 2004-02-17 Ludwig Institute For Cancer Research Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
ES2146648T3 (es) 1993-03-09 2000-08-16 Genzyme Corp Procedimiento de aislamiento de proteinas de la leche.
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5608082A (en) 1994-07-28 1997-03-04 Agouron Pharmaceuticals, Inc. Compounds useful as antiproliferative agents and GARFT inhibitors
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US6046037A (en) 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
KR100479146B1 (ko) 1995-04-21 2005-05-16 셀 제네시스, 인코포레이티드 큰게놈dna결실유발법
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
JP2000514777A (ja) * 1995-08-14 2000-11-07 クリエイティブ バイオモレキュールズ，インコーポレイテッド 骨形成タンパク質（ｏｐ−１）およびそのアナログの細胞表面レセプターａｌｋ−１およびそのアナログへの結合
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US5663272A (en) 1995-12-22 1997-09-02 Bayer Corporation Allophanate-modified diphenylmethane diisocyanates and processes for their production and use
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
US6180651B1 (en) 1996-04-04 2001-01-30 Bristol-Myers Squibb Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics
ATE233743T1 (de) 1996-04-12 2003-03-15 Searle & Co N-((4-(5-methyl-3-phenylisoxazol-4- yl)phenyl)sulphonylpropylamid und sein natriumsalz als pro-pharmakon von cox-2 inhibitoren
DE19616523A1 (de) * 1996-04-25 1997-11-06 Basf Ag Polymerisationskatalysatoren mit beta-Diketiminat-Liganden
CA2259222A1 (en) 1996-06-27 1997-12-31 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
PT912559E (pt) 1996-07-13 2003-03-31 Glaxo Group Ltd Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase
CN1230185A (zh) 1996-07-13 1999-09-29 葛兰素集团有限公司 双环芳杂环化合物用作蛋白质酪氨酸激酶的抑制剂
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
SI0912518T1 (en) 1996-07-18 2003-12-31 Merck Frosst Canada & Co. Substituted pyridines as selective cyclooxygenase-2 inhibitors
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
WO2002024719A1 (en) 2000-09-20 2002-03-28 Human Genome Sciences, Inc. 21 human secreted proteins
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
JP2002511852A (ja) 1997-05-07 2002-04-16 スージェン・インコーポレーテッド 蛋白質キナーゼ活性の調節剤としての２−インドリノン誘導体
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
EP0984692A4 (en) 1997-05-30 2001-02-21 Merck & Co Inc ANGIOGENESIS INHIBITORS
AU8816298A (en) 1997-08-22 1999-03-16 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
AU744939B2 (en) 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
KR100446363B1 (ko) 1997-11-11 2004-09-01 화이자 프로덕츠 인코포레이티드 항암제로 유용한 티에노피리미딘 및 티에노피리딘 유도체
JPH11236333A (ja) 1997-12-30 1999-08-31 Pfizer Prod Inc 抗ガン剤として有用なイミダゾリン−４−オン誘導体
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
WO1999045031A2 (en) 1998-03-03 1999-09-10 Abgenix, Inc. Cd147 binding molecules as therapeutics
EP2078752A3 (en) * 1998-03-13 2009-09-23 Ludwig Institute For Cancer Research ALK-1 responds to TGF-beta and signals through SMAD-1 and SMAD-5
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
EP1082305A4 (en) 1998-05-29 2001-09-26 Sugen Inc PYRROL SUBSTITUTED 2-INDOLINONE EFFECTIVE AS A PROTEIN KINASE INHIBITOR
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
WO2000009560A2 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
BR9913315A (pt) 1998-08-27 2001-05-22 Pfizer Prod Inc Derivados de quinolin-2-ona úteis como agentes anticâncer
WO2000012499A1 (en) 1998-08-27 2000-03-09 Pfizer Products Inc. Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
EP1006113A1 (en) 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
HK1042096A1 (zh) 1999-02-11 2002-08-02 辉瑞产品公司 可用作抗癌剂的杂芳基取代的喹啉-2-酮衍生物
US5998206A (en) * 1999-02-23 1999-12-07 Isis Pharmaceuticals Inc. Antisense inhibiton of human G-alpha-12 expression
US6586447B1 (en) 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
DE60022383T2 (de) 1999-11-05 2006-03-09 Amada Co., Ltd., Isehara Biegepresse und verfahren zum steuern einer bidirektionalen flüssigkeitspumpe eines hydraulikzylinders einer biegepresse
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
TR200400342T4 (tr) 1999-11-30 2004-03-22 Pfizer Products Inc. Farnezil protein transferazı önlemek için kinolin türevleri.
WO2001043763A1 (en) * 1999-12-15 2001-06-21 Research Development Foundation Betaglycan as an inhibin receptor and uses thereof
MXPA02008021A (es) 2000-02-15 2004-04-05 Sugen Inc Indolinonas sustituidas con pirroles inhibidoras de proteinquinasas.
US6584504B1 (en) 2000-05-26 2003-06-24 Networks Associates Technology, Inc. Method and apparatus for monitoring internet traffic on an internet web page
OA12291A (en) 2000-06-22 2004-03-18 Pfizer Prod Inc Substituted bicyclic derivatives for the treatmentof abnormal cell growth.
ES2344592T3 (es) 2001-01-05 2010-09-01 Pfizer Inc. Anticuerpos frente al receptor del factor de crecimiento similar a la insulina i.
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
ATE374214T1 (de) * 2001-04-27 2007-10-15 Kirin Brewery Monoklonaler anti-cd-40-antikörper
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
WO2003048328A2 (en) * 2001-12-03 2003-06-12 Abgenix, Inc. Antibodies against carboxic anhydrase ix (ca ix) tumor antigen
WO2003048731A2 (en) 2001-12-03 2003-06-12 Abgenix, Inc. Antibody categorization based on binding characteristics
EP1467756A4 (en) * 2001-12-28 2007-03-21 Abgenix Inc METHODS OF USING ANTI-MUC18 ANTIBODIES
PA8580301A1 (es) 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
US7285269B2 (en) * 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
CN103087970B (zh) 2005-02-04 2016-12-21 Cp凯尔科美国公司 多糖粘液形成菌的靶基因缺失
UA94060C2 (ru) * 2005-09-07 2011-04-11 Эмджен Фримонт Инк. Моноклональное антитело, которое специфически связывает alk-1
JP6943759B2 (ja) 2017-12-28 2021-10-06 株式会社東海理化電機製作所 シフト装置

Also Published As

Publication number Publication date
IL189642A (en) 2013-06-27
AP2723A (en) 2013-08-31
US8080646B2 (en) 2011-12-20
JP5161777B2 (ja) 2013-03-13
HUE025608T2 (en) 2016-03-29
CL2010000096A1 (es) 2010-06-25
TW201030017A (en) 2010-08-16
CN101517068B (zh) 2017-02-08
KR101536487B1 (ko) 2015-07-13
NL1032452A1 (nl) 2007-03-08
JP5947840B2 (ja) 2016-07-06
US9221915B2 (en) 2015-12-29
CR9819A (es) 2008-12-03
SI1933871T1 (sl) 2013-10-30
ME00501B (me) 2011-10-10
ES2681656T3 (es) 2018-09-14
TW201431883A (zh) 2014-08-16
KR20130042648A (ko) 2013-04-26
WO2007040912A2 (en) 2007-04-12
PT1933871E (pt) 2013-07-17
EP3381945A1 (en) 2018-10-03
LT2960253T (lt) 2018-10-10
PE20080035A1 (es) 2008-01-30
EA201300320A1 (ru) 2014-02-28
EP2447283A3 (en) 2012-06-20
AU2006297571A1 (en) 2007-04-12
TWI453218B (zh) 2014-09-21
GEP20125398B (en) 2012-02-27
KR20140004261A (ko) 2014-01-10
CN107056943A (zh) 2017-08-18
GT200600406A (es) 2007-07-13
US7537762B2 (en) 2009-05-26
AU2006297571A2 (en) 2008-05-01
UY29783A1 (es) 2007-04-30
ZA200802971B (en) 2009-10-28
EP2447283B1 (en) 2015-07-15
PT2960253T (pt) 2018-07-31
CR20130351A (es) 2013-08-13
WO2007040912A3 (en) 2009-04-30
KR20080045715A (ko) 2008-05-23
TWI569807B (zh) 2017-02-11
IL218429A0 (en) 2012-04-30
PL2447283T3 (pl) 2015-12-31
DOP2006000195A (es) 2017-08-15
SI2447283T1 (sl) 2015-12-31
JP5833978B2 (ja) 2015-12-16
US20100197005A1 (en) 2010-08-05
AU2006297571B2 (en) 2012-03-15
EP1933871B1 (en) 2013-04-24
CA2621371C (en) 2018-05-15
NO20081718L (no) 2008-06-03
TWI541253B (zh) 2016-07-11
EP3381945B1 (en) 2020-08-19
EA018453B1 (ru) 2013-08-30
JP2009506791A (ja) 2009-02-19
MY164457A (en) 2017-12-15
IL189642A0 (en) 2008-06-05
RS20080103A (en) 2009-07-15
TW200801043A (en) 2008-01-01
CN107056943B (zh) 2021-06-08
EP2960253A1 (en) 2015-12-30
MA29843B1 (fr) 2008-10-03
EP1933871A2 (en) 2008-06-25
AP2008004388A0 (en) 2008-04-30
PL2960253T3 (pl) 2018-11-30
DK2447283T3 (en) 2015-08-31
EP2447283A2 (en) 2012-05-02
HN2006031275A (es) 2010-10-29
CN101517068A (zh) 2009-08-26
TW201511773A (zh) 2015-04-01
CR20140239A (es) 2014-06-13
US20120052074A1 (en) 2012-03-01
TNSN08080A1 (en) 2009-07-14
PT2447283E (pt) 2015-10-08
PL1933871T3 (pl) 2013-09-30
EP1933871A4 (en) 2009-10-28
TW201311728A (zh) 2013-03-16
HK1219488A1 (en) 2017-04-07
AP2013006963A0 (en) 2013-07-31
CA2621371A1 (en) 2007-04-12
UA94060C2 (ru) 2011-04-11
AR055152A1 (es) 2007-08-08
KR101536506B1 (ko) 2015-07-14
BRPI0615766A2 (pt) 2009-06-16
EA200800759A1 (ru) 2008-08-29
RS54393B1 (sr) 2016-04-28
TWI389919B (zh) 2013-03-21
JP2014218514A (ja) 2014-11-20
EP2960253B1 (en) 2018-06-06
HUE038941T2 (hu) 2018-12-28
HK1169999A1 (en) 2013-02-15
CY1120794T1 (el) 2019-12-11
ES2546069T3 (es) 2015-09-18
DK2960253T3 (en) 2018-08-13
ES2421146T3 (es) 2013-08-29
NZ566774A (en) 2011-11-25
US20070065444A1 (en) 2007-03-22
JP2012228251A (ja) 2012-11-22
NL1032452C2 (nl) 2008-01-18
SI2960253T1 (sl) 2018-10-30
AR107003A2 (es) 2018-03-07
KR101390127B1 (ko) 2014-05-13
DK1933871T3 (da) 2013-07-08

Similar Documents

Publication Publication Date Title
TWI370137B (en) Human monoclonal antibodies to activin receptor-like kinase-1
HRP20181616T1 (hr) Potpuno ljudska anti-vap-1 monoklonska antitijela
IL191340A (en) Monoclonal antibodies against e8o
IL189788A0 (en) Human monoclonal antibodies to cd70
IL216381A0 (en) Antagonistic human light-specific human monoclonal antibodies
IL179672A0 (en) Anti-cd3 antibodies
ZA200802051B (en) Anti-CD3 antibody formulations
IL231169A0 (en) Human monoclonal antibodies to fucosil - 1gm and methods of using antibodies against fucosil - 1gm
IL177602A0 (en) Uses of anti-ctla-4 antibodies
ZA200802641B (en) Human monoclonal antibodies to CD70
ZA200901165B (en) Antagonistic human light-specific human monoclonal antibodies
ZA200804254B (en) Human monoclonal antibodies to O8E
HK1122825A (en) Human monoclonal antibodies to o8e

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees